company background image
IRX

InhaleRxASX:IRX Stock Report

Market Cap

AU$17.7m

7D

0%

1Y

75.0%

Updated

21 Oct, 2021

Data

Company Financials
IRX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

IRX Overview

InhaleRx Limited offers medical inhalation devices for the delivery of prescribed medicines in Australia and internationally.

Price History & Performance

Summary of all time highs, changes and price drops for InhaleRx
Historical stock prices
Current Share PriceAU$0.10
52 Week HighAU$0.059
52 Week LowAU$0.14
Beta-0.50
1 Month Change29.63%
3 Month Change-4.55%
1 Year Change75.00%
3 Year Change41.89%
5 Year Changen/a
Change since IPO-73.75%

Recent News & Updates

Shareholder Returns

IRXAU Healthcare ServicesAU Market
7D0%0.2%0.7%
1Y75.0%41.1%21.4%

Return vs Industry: IRX exceeded the Australian Healthcare Services industry which returned 39.9% over the past year.

Return vs Market: IRX exceeded the Australian Market which returned 21.1% over the past year.

Price Volatility

Is IRX's price volatile compared to industry and market?
IRX volatility
IRX Beta-0.50
Industry Beta0.49
Market Beta1

Stable Share Price: IRX is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: IRX's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2016n/aMatthew Goldenhttps://inhalerx.com.au

InhaleRx Limited offers medical inhalation devices for the delivery of prescribed medicines in Australia and internationally. Its solutions include Medihale inhaler, a sealed pod inhaler for use with medical cannabis inhaled formulations. The company was formerly known as Lifespot Health Ltd and changed its name to InhaleRx Limited in October 2021.

InhaleRx Fundamentals Summary

How do InhaleRx's earnings and revenue compare to its market cap?
IRX fundamental statistics
Market CapAU$17.69m
Earnings (TTM)-AU$1.30m
Revenue (TTM)AU$22.48k

807.7x

P/S Ratio

-13.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IRX income statement (TTM)
RevenueAU$22.48k
Cost of RevenueAU$168.87k
Gross Profit-AU$146.39k
ExpensesAU$1.15m
Earnings-AU$1.30m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.0077
Gross Margin-651.32%
Net Profit Margin-5,767.44%
Debt/Equity Ratio0.0%

How did IRX perform over the long term?

See historical performance and comparison

Valuation

Is InhaleRx undervalued compared to its fair value and its price relative to the market?

5.63x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IRX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IRX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IRX is unprofitable, so we can't compare its PE Ratio to the Global Healthcare Services industry average.

PE vs Market: IRX is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IRX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IRX is overvalued based on its PB Ratio (5.6x) compared to the AU Healthcare Services industry average (4.2x).


Future Growth

How is InhaleRx forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

40.8%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as InhaleRx has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has InhaleRx performed over the past 5 years?

5.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IRX is currently unprofitable.

Growing Profit Margin: IRX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IRX is unprofitable, but has reduced losses over the past 5 years at a rate of 5.7% per year.

Accelerating Growth: Unable to compare IRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IRX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (39.5%).


Return on Equity

High ROE: IRX has a negative Return on Equity (-41.23%), as it is currently unprofitable.


Financial Health

How is InhaleRx's financial position?


Financial Position Analysis

Short Term Liabilities: IRX's short term assets (A$3.6M) exceed its short term liabilities (A$508.2K).

Long Term Liabilities: IRX has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: IRX is debt free.

Reducing Debt: IRX has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IRX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: IRX has sufficient cash runway for 2.5 years if free cash flow continues to grow at historical rates of 7.9% each year.


Dividend

What is InhaleRx current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IRX's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average management tenure


CEO

Matthew Golden

1

Tenure

AU$180,557

Compensation

Mr. Matthew Golden serves as Chief Executive Officer at InhaleRx Limited (formerly known as Lifespot Health Ltd) since October 12, 2020. Mr. Golden is a commercial healthcare Professional with experience i...


CEO Compensation Analysis

Compensation vs Market: Matthew's total compensation ($USD135.22K) is below average for companies of similar size in the Australian market ($USD303.55K).

Compensation vs Earnings: Insufficient data to compare Matthew's compensation with company performance.


Leadership Team

Experienced Management: IRX's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: IRX's board of directors are not considered experienced ( 0.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: IRX insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 38.5%.


Top Shareholders

Company Information

InhaleRx Limited's employee growth, exchange listings and data sources


Key Information

  • Name: InhaleRx Limited
  • Ticker: IRX
  • Exchange: ASX
  • Founded: 2016
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: AU$17.689m
  • Shares outstanding: 168.47m
  • Website: https://inhalerx.com.au

Location

  • InhaleRx Limited
  • 2 Queen Street
  • Suite 103
  • Melbourne
  • Victoria
  • 3000
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/21 18:20
End of Day Share Price2021/10/21 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.